Why Assigning Patents To Native American Tribes To Avoid Inter Partes Review Is Bad Medicine
Here are three big reasons why, according to IP columnist Tom Kulik.
A New Patent Loophole? Paying Off A Native American Tribe To Exploit Its Sovereign Immunity
If this tactic is allowed, it will be a big win for Big Pharma -- and a big loss for patients and consumers.
Skills That Set Firms Apart
Legal expertise alone isn’t enough. Today’s most successful firms invest in developing the skills that drive collaboration, leadership, and business growth. Our on-demand, customizable training modules deliver practical, high-impact learning for attorneys and staff—when and where they need it.
Pharma Companies Routinely Bend Rules Under Orphan Drug Act
A Kaiser Health News investigation shows that the system intended to help desperate patients is being manipulated by drugmakers to maximize profits,
Biglaw Firm Gets Benchslapped Over Conflicts
Which Biglaw firm got blasted for ignoring its ethical obligations in a hostile takeover bid?
When Buying Off A Litigant Is Also Buying Off A Competitor
According to the Supreme Court, sometimes settling a lawsuit can create an antitrust problem. How?
Inside Straight: Learning Who To Hate
Cops learn to hate people. Basically everyone they encounter is a criminal, so cops soon come to believe that everyone is a criminal. Litigators — or perhaps litigators who are repeat players in a particular field — learn to hate people. Personal injury insurance defense counsel come to believe that all plaintiffs are lying fakers. […]
Decrypting Crypto, Digital Assets, And Web3
"Decrypting Crypto" is a go-to guide for understanding the technology and tools underlying Web3 and issues raised in the context of specific legal practice areas.
Inside Straight: Pfortune On Pfizer
Columnist Mark Herrmann thinks that you should read the long piece in Fortune magazine about the rise and fall of Jeff Kindler as the CEO of Pfizer because it gives some insight on life as an in-house attorney....
Skaddenfreude: In-House Salaries, Please
This item, from yesterday’s WSJ Law Blog, caught our eye: As the 11th Vioxx trial got underway yesterday in federal court in New Orleans, Merck disclosed in an SEC filing that it’s giving its general counsel Kenneth Frazier a raise and a promotion, effective Nov. 1. The GC who will forever be associated with the […]